ReviewMicroorganisms2022
Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Trends in Comorbidity for Patients with Venous Thromboembolism in a General Hospital: 2018 to 2022.Clinics and practice · 2026Article
- Pulmonary Embolism in Hospitalized COVID-19 Patients: Incidence, Clinical Predictors, and Short-Term Outcomes.Journal of clinical medicine · 2026Article
- Short and long-term outcomes of COVID-19-associated venous thromboembolism: a propensity score-matched cohort study.Internal and emergency medicine · 2025Article
- Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection.Lancet regional health. Americas · 2025Article
- Impact of Natriuretic Peptide on the Evolution of Patients With Pulmonary Embolism and Neoplasm.Cureus · 2024Article
- Venous Thromboembolism Management throughout the COVID-19 Era: Addressing Acute and Long-Term Challenges.Journal of clinical medicine · 2024Article
- Article
- A study of clinical and serological correlation of early myocardial injury in elderly patients infected with the Omicron variant.Frontiers in cardiovascular medicine · 2024Article
- Article
- A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology.International journal of molecular sciences · 2023Review
- Mechanical Thrombectomy in Acute Ischemic Stroke COVID-19 and Non-COVID-19 Patients: A Single Comprehensive Stroke Center Study.Life (Basel, Switzerland) · 2023Article
- Prevalence and clinical implications of atrial fibrillation in patients hospitalized due to COVID-19: Data from a registry in Poland.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The infection with the SARS-CoV-2 virus is associated with numerous systemic involvements. Besides the severe respiratory injuries and cardiovascular complications, it became obvious early on that this disease carries an increased risk of thromboembolic events, but a higher propensity for bleedings as well. We researched the medical literature over significant PubMed published articles debating on the prevalence, category of patients, the moment of occurrence, and evolution of venous thromboembolism (VTE), but also of venous and arterial "in situ" thrombosis (AT), and hemorrhagic events as well. Most researchers agree on an increased prevalence of thromboembolic events, ranging between 25 and 31% for VTE, depending on the analyzed population. For AT and hemorrhagic complications lower rates were reported, namely, about 2-3%, respectively, between 4.8 and 8%, occurring mostly in older patients, suffering from moderate/severe forms of COVID-19, with associated comorbidities. It is important to mention that patients suffering from hemorrhages frequently received thromboprophylaxis with anticoagulant drugs. As a consequence of thromboembolic and hemorrhagic complications which are both important negative prognostic factors, the evolution of patients infected with the SARS-CoV-2 virus is aggravated, determining an augmented morbidity and mortality of this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.